U.K. approved its first CRISPR gene-editing drug. U.S. could follow
Last week, in a global milestone for medicine, U.K. regulators approved the first-ever CRISPR gene-editing drug. The treatment, from Vertex and CRISPR Therapeutics, will be licensed under the brand name Casgevy in the U.K. for patients with sickle cell disease (SCD) and beta thalassemia. The regulatory green light abroad isn’t surprising given the therapy’s established record of clinical trial success in treating these painful, and sometimes fatal, inherited blood disorders. But it marks a historic turning point for…